Oramed Pharmaceuticals (ORMP) Profit After Tax (2011 - 2026)

Oramed Pharmaceuticals' Profit After Tax history runs 15 years deep, the most recent figure standing at $38.3 million for Q1 2026.

• Quarterly Profit After Tax rose 601.31% year-over-year to $38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.3 million (up 557.65% YoY) and the FY2025 annual result came in at $64.0 million, up 435.29% from the prior year.
• Profit After Tax was $38.3 million for Q1 2026 at Oramed Pharmaceuticals, up from $29.3 million in the prior quarter.
• Across five years, Profit After Tax topped out at $48.4 million in Q3 2025 and bottomed at -$19.6 million in Q3 2024.
• A 5-year average of $3.9 million and a median of -$3.2 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax soared 871.52% — and 2025, when it sank 597.53%.
• Oramed Pharmaceuticals' Profit After Tax stood at -$12.3 million in 2022, then soared by 205.25% to $12.9 million in 2023, then sank by 179.07% to -$10.2 million in 2024, then soared by 387.41% to $29.3 million in 2025, then soared by 30.69% to $38.3 million in 2026.
• Business Quant data shows ORMP's Profit After Tax at $38.3 million in Q1 2026, $29.3 million in Q4 2025, and $48.4 million in Q3 2025.